{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:19:18Z","timestamp":1777990758955,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00392-019-01432-y","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T12:20:07Z","timestamp":1550060407000},"page":"1034-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes"],"prefix":"10.1007","volume":"108","author":[{"given":"Kazuo","family":"Miyazawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Guang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Sz\u00e9kely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhan","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"key":"1432_CR1","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jacc.2015.06.1314","volume":"66","author":"RA Vermond","year":"2015","unstructured":"Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, Van Gilst WH, Van Gelder IC, Rienstra M (2015) Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands. J Am Coll Cardiol 66:1000\u20131007","journal-title":"J Am Coll Cardiol"},{"key":"1432_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip GYH (2017) The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 14:627\u2013628","journal-title":"Nat Rev Cardiol"},{"key":"1432_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mayocp.2018.10.022","volume":"1","author":"D Pastori","year":"2018","unstructured":"Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH (2018) Integrated care management of patients with atrial fibrillation and risk of cardiovascular events: the ABC (atrial fibrillation better care) pathway in the ATHERO-AF study cohort. Mayo Clin Proc 1:1. \n                    https:\/\/doi.org\/10.1016\/j.mayocp.2018.10.022","journal-title":"Mayo Clin Proc"},{"key":"1432_CR4","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S0140-6736(16)30968-0","volume":"388","author":"JS Healey","year":"2016","unstructured":"Healey JS, Oldgren J, Ezekowitz M et al (2016) Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet 388:1161\u20131169","journal-title":"Lancet"},{"key":"1432_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1161\/STROKEAHA.108.516344","volume":"40","author":"DJ Gladstone","year":"2009","unstructured":"Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK (2009) Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40:235\u2013240","journal-title":"Stroke"},{"key":"1432_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1023\/A:1009823001707","volume":"4","author":"I Savelieva","year":"2000","unstructured":"Savelieva I, Camm AJ (2000) Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 4:369\u2013382","journal-title":"J Interv Card Electrophysiol"},{"key":"1432_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1161\/01.STR.26.9.1527","volume":"26","author":"HJ Lin","year":"1995","unstructured":"Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D\u2019Agostino RB (1995) Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study. Stroke 26:1527\u20131530","journal-title":"Stroke"},{"key":"1432_CR8","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/europace\/eux177","volume":"19","author":"GH Mairesse","year":"2017","unstructured":"Mairesse GH, Moran P, Van Gelder IC et al (2017) Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace 19:1589\u20131623","journal-title":"Europace"},{"key":"1432_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1046\/j.1460-9592.2001.00424.x","volume":"24","author":"WM Pollak","year":"2001","unstructured":"Pollak WM, Simmons JD, Interian A Jr, Atapattu SA, Castellanos A, Myerburg RJ, Mitrani RD (2001) Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter. Pacing Clin Electrophysiol 24:424\u2013429","journal-title":"Pacing Clin Electrophysiol"},{"key":"1432_CR10","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/01.CIR.0000057981.70380.45","volume":"107","author":"TV Glotzer","year":"2003","unstructured":"Glotzer TV, Hellkamp AS, Zimmerman J et al (2003) Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 107:1614\u20131619","journal-title":"Circulation"},{"key":"1432_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1161\/CIRCEP.109.849638","volume":"2","author":"TV Glotzer","year":"2009","unstructured":"Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD (2009) The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2:474\u2013480","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1432_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1105575","volume":"366","author":"JS Healey","year":"2012","unstructured":"Healey JS, Connolly SJ, Gold MR et al (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:120\u2013129","journal-title":"N Engl J Med"},{"key":"1432_CR13","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"1432_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837\u2013845","journal-title":"Biometrics"},{"key":"1432_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina MJ, D\u2019Agostino RB, D\u2019Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157\u2013172 (discussion 207-112)","journal-title":"Stat Med"},{"key":"1432_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26:565\u2013574","journal-title":"Med Decis Making"},{"key":"1432_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.pcad.2017.12.002","volume":"60","author":"K Miyazawa","year":"2018","unstructured":"Miyazawa K, Pastori D, Lip GYH (2018) Quantifying time in atrial fibrillation and the need for anticoagulation. Prog Cardiovasc Dis 60:537\u2013541","journal-title":"Prog Cardiovasc Dis"},{"key":"1432_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrcardio.2017.94","volume":"14","author":"B Freedman","year":"2017","unstructured":"Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS (2017) Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 14:701\u2013714","journal-title":"Nat Rev Cardiol"},{"key":"1432_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/eurheartj\/ehx731","volume":"39","author":"R Mahajan","year":"2018","unstructured":"Mahajan R, Perera T, Elliott AD et al (2018) Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J 39:1407\u20131415","journal-title":"Eur Heart J"},{"key":"1432_CR20","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1056\/NEJMoa013040","volume":"346","author":"GA Lamas","year":"2002","unstructured":"Lamas GA, Lee KL, Sweeney MO et al (2002) Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 346:1854\u20131862","journal-title":"N Engl J Med"},{"key":"1432_CR21","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1161\/01.CIR.0000072769.17295.B1","volume":"107","author":"MO Sweeney","year":"2003","unstructured":"Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA, Investigators MOST (2003) Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 107:2932\u20132937","journal-title":"Circulation"},{"key":"1432_CR22","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jacc.2007.04.096","volume":"50","author":"D Yannopoulos","year":"2007","unstructured":"Yannopoulos D, Lurie KG, Sakaguchi S, Milstein S, Ermis C, VanHeel L, Benditt DG (2007) Reduced atrial tachyarrhythmia susceptibility after upgrade of conventional implanted pulse generator to cardiac resynchronization therapy in patients with heart failure. J Am Coll Cardiol 50:1246\u20131251","journal-title":"J Am Coll Cardiol"},{"key":"1432_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/europace\/eur293","volume":"14","author":"N Shanmugam","year":"2012","unstructured":"Shanmugam N, Boerdlein A, Proff J, Ong P, Valencia O, Maier SK, Bauer WR, Paul V, Sack S (2012) Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace Feb 14:230\u2013237","journal-title":"Europace Feb"},{"key":"1432_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1540-8167.2008.01320.x","volume":"20","author":"GL Botto","year":"2009","unstructured":"Botto GL, Padeletti L, Santini M et al (2009) Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 20:241\u2013248","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1432_CR25","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1161\/STROKEAHA.110.609297","volume":"42","author":"G Boriani","year":"2011","unstructured":"Boriani G, Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Ricci R, Biffi M, De Santo T, Corbucci G, Lip GY, Italian ATRI (2011) Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke 42:1768\u20131770","journal-title":"Stroke"},{"key":"1432_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ahj.2017.04.008","volume":"189","author":"RD Lopes","year":"2017","unstructured":"Lopes RD, Alings M, Connolly SJ et al (2017) Rationale and design of the Apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESiA) trial. Am Heart J 189:137\u2013145","journal-title":"Am Heart J"},{"key":"1432_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ahj.2017.04.015","volume":"190","author":"P Kirchhof","year":"2017","unstructured":"Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P (2017) Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J 190:12\u201318","journal-title":"Am Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-019-01432-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01432-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01432-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T19:06:29Z","timestamp":1581534389000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-019-01432-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1432"],"URL":"https:\/\/doi.org\/10.1007\/s00392-019-01432-y","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"assertion":[{"value":"9 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No author has a specific conflict of interest in the publication of this study. GYHL: Consultant for Bayer\/Janssen, BMS\/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo; Speaker for Bayer, BMS\/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. GB: Speaker for Biotronik, Boehringer Ingelheim, Boston Scientific and Medtronic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}